TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions
For people with early Alzheimer's (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of…